drugset / Trial / NCT03781362
Study of CPI-100 in Patients With Advanced Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).
Timeline
- Start
- 2018-12-21
- Primary completion
- 2022-06-21
- Completion
- 2022-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPI-100 | Unknown | — | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
Indications
No indication recorded.